Searched for
DRUG MAJOR CIPLA
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- Cipla to acquire South Africa-based Actor PharmaActor was founded in 2009 and has quickly grown to become the fifth largest privately owned OTC player in the South African market. Actor s...
- Cipla unit gets notice from US firm for termination of acquisition deal"Since the second stage closing could not be completed as per the agreed timelines, in the terms of the SPMA, InvaGen has received a notice...
- Cipla gets USFDA nod for migraine drugThe newly approved product is a generic therapeutic equivalent version of GlaxoSmithKline's Imitrex Nasal Spray.
- Cipla submits application with USFDA for generic version of asthma drugDrug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, ...
- Cipla gets CCI nod for investment by FIL CapitalDrug major Cipla said it has received approval from CCI over the proposed investment by Mauritius-based FIL Capital Investments.
- Cipla weighs legal options after Delhi HC's patent rulingDrug major Cipla is exploring all legal options in the wake of Delhi High Court's ruling that it has infringed Swiss drug major Hoffman-La ...
- Cipla elevates Samina Vaziralli to its boardCipla today announced the appointment of Samina Vaziralli as executive director on its board, paving way for a bigger role for her.
- Stempeutics' Stempeucel gets Orphan Drug status in EuropeAn orphan designation allows a company to benefit from incentives from the European Union to develop a medicine for a rare disease.
- Cipla expected to post good performance in March quarterThe co’s export business that earns almost half of its total revenues, is expected to grow at 40%. The growth in its domestic business is e...
- Cipla receives nod from South Africa authorities to acquire Cipla MedproCipla Ltd today said it has received approval from South Africa and Botswana for the $ 512 million takeover offer to acquire Cipla Medpro
- Cipla launches biosimilar for rheumatic disorders in IndiaDrug major Cipla said it has launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in ...
- Cipla launches HIV/AIDS treatment kit at Rs 158Drug major Cipla today said it has launched 'Qvir', a four-drug kit priced at Rs 158 per kit to be used for treating HIV/AIDS.
- Cipla approves special interim dividend; acquisition of MeditabDrug major Cipla today said its board has approved the acquisition of Mumbai-based Meditab Specialities for a consideration of Rs 133.35 cr...
- Roche sues Cipla over Valcyte patent breachSwiss major Roche has moved the Bombay High Court (HC) against domestic major Cipla for allegedly infringing both the patent and trademark ...
- PEs to bankroll Cipla's Merck bidIndian drug major Cipla and private equity (PE) funds are working out an innovative financing model to bid for Merck’s generic business.
Load More
